臨床外科79巻7号

2024年07月発行

特集 外科医が知っておくべき 肝胆膵腫瘍に対する薬物療法

胆道・膵臓

切除不能・再発胆道癌に対する薬物療法

著者： 手塚瞬¹ 上野誠¹

所属機関： ¹神奈川県立がんセンター消化器内科肝胆膵

ページ範囲：P.744 - P.750

文献概要

【ポイント】
◆治癒切除不能な胆道癌の一次治療として，ゲムシタビンとシスプラチンとの併用に免疫チェックポイント阻害薬のデュルバルマブおよびペムブロリズマブをそれぞれ上乗せする2つのレジメンが標準治療に加わった．
◆治癒切除不能な胆道癌の二次治療では，遺伝子異常別の治療開発が積極的に行われており，fibroblast growth factor receptor（FGFR）2融合遺伝子陽性の胆道癌に対してペミガチニブおよびフチバチニブがそれぞれ薬事承認されている．

参考文献

1）日本肝胆膵外科学会胆道癌診療ガイドライン作成委員会（編）；エビデンスに基づいた胆道癌診療ガイドライン（改訂第3版）．医学図書出版，2019

2）National Comprehensive Cancer Network（NCCN）：Biliary tract cancers（v3.2023）. 2023［Available from：https://www.nccn.org/professionals/physician_gls/pdf/btc.pdf

3）Oh DY, He AR, Qin S, et al：Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1：EVIDoa2200015, 2022

4）Kelley RK, Ueno M, Yoo C, et al：Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer（KEYNOTE-966）：a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 401：1853-1865, 2023

5）Ioka T, Kanai M, Kobayashi S, et al：Randomized phase Ⅲ study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer（KHBO1401- MITSUBA）. J Hepatobiliary Pancreat Sci 30：102-110, 2023

6）Kobayashi S, Ueno M, Ohkawa S, et al：A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer. Jpn J Clin Oncol 42：800-806, 2012

7）Sasaki T, Isayama H, Nakai Y, et al：Multicenter phase Ⅱ study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 30：708-713, 2012

8）Suzuki E, Ikeda M, Okusaka T, et al：A multicenter phase Ⅱ study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol 71：1141-1146, 2013

9）Nakamura H, Arai Y, Totoki Y, et al：Genomic spectra of biliary tract cancer. Nat Genet 47：1003-1010, 2015

10）Okawa Y, Ebata N, Kim NKD, et al：Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase. Oncotarget 12：1540-1552, 2021

11）Arai Y, Totoki Y, Hosoda F, et al：Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 59：1427-1434, 2014

12）Abou-Alfa GK, Sahai V, Hollebecque A, et al：Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma：a multicentre, open-label, phase 2 study. Lancet Oncol 21：671-684, 2020

13）Goyal L, Meric-Bernstam F, Hollebecque A, et al：Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Medi 388：228-239, 2023

14）Lin Q, Chen X, Qu L, et al：Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants. Commun Chem 5：100, 2022

15）Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al：TAS-120 cancer target binding：defining reactivity and revealing the first fibroblast growth factor receptor 1（FGFR1）irreversible structure. ChemMedChem 14：494-500, 2019

16）Dai S, Zhou Z, Chen Z, et al：Fibroblast growth factor receptors（FGFRs）：structures and small molecule inhibitors. Cells 8：614, 2019

17）Silverman IM, Hollebecque A, Friboulet L, et al：Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov 11：326-339, 2021

18）Goyal L, Shi L, Liu LY, et al：TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov 9：1064-1079, 2019

19）Akagi K, Oki E, Taniguchi H, et al：The real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 2021, Jan 11. doi://10.1111/cas.14804.

20）Maio M, Ascierto PA, Manzyuk L, et al：Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers：updated analysis from the phase Ⅱ KEYNOTE-158 study. Ann Oncol 33：929-938, 2022

21）Shao C, Li G, Huang L, et al：Prevalence of high tumor mutational burden and association with survival in patients with less common solid tumors. JAMA Netw Open 3：e2025109, 2020

22）Marabelle A, Fakih M, Lopez J, et al：Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab：prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21：1353-1565, 2020

23）Subbiah V, Lassen U, Élez E, et al：Dabrafenib plus trametinib in patients with BRAF（V600E）-mutated biliary tract cancer（ROAR）：a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 21：1234-1243, 2020

24）Boscoe AN, Rolland C, Kelley RK：Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma：a systematic literature review. J Gastrointest Oncol 10：751-765, 2019

25）Zhu AX, Macarulla T, Javle MM, et al：Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation：the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol 7：1669-1677, 2021

26）Harding JJ, Fan J, Oh DY, et al：Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer（HERIZON-BTC-01）：a multicentre, single-arm, phase 2b study. Lancet Oncol 24：772-782, 2023

27）Nakamura Y, Mizuno N, Sunakawa Y, et al：Tucatinib and Trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer（SGNTUC-019）：a phase Ⅱ basket study. J Clin Oncol 41：5569-5578, 2023

28）Lamarca A, Palmer DH, Wasan HS, et al：Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer（ABC-06）：a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22：690-701, 2021